Company news
Percheron Therapeutics Limited (ASX:PER) news
Percheron Therapeutics Limited news releases on 6ix. Latest, Jul 13, 2022: ATL1102 DMD Clinical Trial Application Submitted in Europe
Press releases — page 2
ATL1102 DMD Clinical Trial Application Submitted in Europe
July 12, 2022
New Indication for ATL1102 Limb Girdle Muscular Dystrophy R2
June 19, 2022
Prospectus
April 11, 2022
Bonus Option Offer
April 11, 2022
Long COVID-19 strategic collaboration with US Experts
February 24, 2022
Dosing commenced in MCRI collaboration animal study
February 7, 2022
Quarterly Report and Appendix 4C
January 26, 2022
Entitlement Offer Results
December 21, 2021
Annual General Meeting Presentation
December 14, 2021
Positive UK PIP Decision & PDCO opinion ratification by EMA
December 13, 2021
ATL1102 Toxicology Protocol submitted to US FDA
December 8, 2021
Investor Presentation
November 1, 2021
Positive PDCO opinion and A$20m Placement
November 1, 2021
Positive feedback received on Paediatric Investigation Plan
September 30, 2021
New data supports ATL1102s broader clinical potential
September 23, 2021
ANP to present new proteomics data at WMS Congress 2021
September 19, 2021
ANP Updates on US Regulatory Plans for ATL1102 in DMD
August 11, 2021
ANP and MCRI new R&D collaboration for ATL1102
June 28, 2021
ATL1102 for DMD EMA PIP feedback and FDA regulatory progress
June 21, 2021
US FDA Feedback on Type C Meeting for ATL1102 in the US
June 1, 2021
Manufacture of ATL1102 clinical supplies for Phase IIb trial
May 26, 2021
US FDA Type C Meeting for ATL1102 in DMD
April 23, 2021
ATL1102 DMD Paediatric Investigation Plan submitted to EMA
February 24, 2021
Half Yearly Report and Half Year Accounts
February 24, 2021
ANP meeting with US FDA granted for ATL1102 in DMD
February 14, 2021
Quarterly Update and Appendix 4C
January 27, 2021
Annual General Meeting Chairmans Address
December 17, 2020
EC grants Orphan Drug Designation for ATL1102 in DMD
December 13, 2020
Receipt of R&D Tax Incentive payment
December 7, 2020
ANP raises A$7.3 million from Oversubscribed Placement
November 10, 2020
ANP to apply for dual listing on Frankfurt Stock Exchange
November 8, 2020
ANP receives US FDA ODD for ATL1102 in DMD
October 25, 2020
Pause in Trading
October 22, 2020
ATL1102 shows significant improvement vs external control
October 1, 2020
US FDA Grants RPDD to ATL1102 for the treatment of DMD
September 30, 2020
Antisense to present new data at WMS Virtual Congress 2020
September 29, 2020
ANP Submits EU Orphan Drug application for ATL1102 in DMD
August 30, 2020
ANP Submits US Orphan Drug application for ATL1102 in DMD
August 2, 2020
EMA DMD Scientific Advice and Regulatory Process Update
July 29, 2020
Trial Met Primary & Exceeded Secondary Endpoint Expectations
May 21, 2020
Appointment of US-based Consultant Medical Director
February 26, 2020
Results in DMD unlock value creation potential of ATL1102
February 5, 2020
Quarterly Update & Appendix 4C
January 30, 2020
Antisense Therapeutics Limited - Listed Options raise $5.5M
January 3, 2020
Positive results reaffirm plans to advance ATL1102 to P2b
December 16, 2019
Suspension from Official Quotation
December 15, 2019
AGM Presentation 2019
December 11, 2019
Dosing completed in ATL1102 Phase II DMD trial
November 19, 2019
Appendix 4C - quarterly
October 24, 2019
Response to ASX Price Query
October 7, 2019